Home › Companies › CytomX Therapeutics, Inc. › 2025-2026

CytomX Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and CytomX Therapeutics, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
115Asset managers
939Fund votes
2026-06-17Meeting date

Proxy season: 2025-2026

Explore CytomX Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by CytomX Therapeutics, Inc.

These tallies are CytomX Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CytomX Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Matthew P. Young	146,742,827	2,062,471	199,664	--	34,599,122	Majority: yes
Elect Director: Elaine V. Jones Ph.D.	131,377,301	17,428,951	198,710	--	34,599,122	Majority: yes
Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.	182,976,052	382,681	245,351	--	--	Majority: yes
Proposal 4. The Company's stockholders approved an amendment to the 2015 Plan, as described in the Proxy Statement.	147,079,951	1,745,001	180,010	--	34,599,122	Majority: yes
Proposal 5. The Company's stockholders approved an amendment to the Company's Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement.	147,375,197	1,468,576	161,189	--	34,599,122	Majority: yes

Source: CytomX Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the CytomX Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 115 asset managers that disclosed a CytomX Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CytomX Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 147,079,951AGAINST: 1,745,001

CytomX Therapeutics, Inc.’s own tally for this item (“Proposal 4. The Company's stockholders approved an amendment to the 2015 Plan, as described in the Proxy Statement.”): 147,079,951 for, 1,745,001 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 217,702,919 outstanding shares: 68% for, 0.9% against (68% of the company cast a for/against vote).

The 109 asset managers below cast 99.6% of the shares they voted on this item FOR (146,256,624 for, 488,358 against).

FOR 99.6%

FOR: 146,256,624 (99.7%)AGAINST: 488,358 (0.3%)ABSTAIN: 927 (0.0%)

Largest asset managers voting on “To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disc” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	63,279,679	0	For
Kynam Capital Management, LP	18,064,452	0	For
Vanguard	10,799,357	5	For
Point72	8,044,603	0	For
PERCEPTIVE ADVISORS LLC	6,669,055	0	For
BlackRock	5,257,909	0	For
State Street	5,025,329	0	For
Venrock Adviser, LLC	4,982,124	0	For
Siren, L.L.C.	3,457,711	0	For
Wellington	2,647,827	0	For
ADAR1 Capital Management, LLC	2,630,102	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,296,163	0	For
MARSHALL WACE, LLP	2,175,824	0	For
Citadel	1,692,085	0	For
Two Sigma	1,655,496	0	For
683 Capital Management, LLC	800,000	0	For
Ensign Peak Advisors, Inc	592,473	0	For
Dimensional	582,860	0	For
Ally Bridge Group (NY) LLC	560,000	0	For
Exome Asset Management LLC	469,978	0	For
Velan Capital Investment Management LP	457,717	0	For
Invesco	453,425	0	For
Northern Trust	363,729	0	For
BALYASNY ASSET MANAGEMENT L.P.	298,256	0	For
HighVista Strategies LLC	288,057	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

2. TO HOLD A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES BY STOCKHOLDERS ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 79%1 YEAR 14%

The 107 asset managers below cast 100% of the shares they voted on this item FOR (7,229,055 for, 0 against).

FOR: 7,229,055 (5.5%)ABSTAIN: 1 (0.0%)ONE YEAR: 103,690,235 (79.1%)1 YEAR: 18,483,692 (14.1%)3 YEARS: 650,537 (0.5%)THREE YEARS: 591,681 (0.5%)1.0: 458,117 (0.3%)1-YEAR: 2,094 (0.0%)3.0: 7 (0.0%)2.0: 4 (0.0%)

Largest asset managers voting on “TO HOLD A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES BY STOCKHOLDERS ON THE COMPENSAT” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	0	0	One Year
Vanguard	0	1	One Year
Point72	0	0	One Year
PERCEPTIVE ADVISORS LLC	6,669,055	0	For
BlackRock	0	0	1 Year
State Street	0	0	One Year
Venrock Adviser, LLC	0	0	One Year
Siren, L.L.C.	0	0	1 Year
Kynam Capital Management, LP	0	0	1 Year
Wellington	0	0	1 Year
ADAR1 Capital Management, LLC	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	One Year
MARSHALL WACE, LLP	0	0	1 Year
Citadel	0	0	One Year
Two Sigma	0	0	One Year
683 Capital Management, LLC	0	0	One Year
Ensign Peak Advisors, Inc	0	0	3 Years
Dimensional	0	0	Three Years
Ally Bridge Group (NY) LLC	560,000	0	For
Velan Capital Investment Management LP	0	0	1.0
Invesco	0	0	One Year
Northern Trust	0	0	1 Year
BALYASNY ASSET MANAGEMENT L.P.	0	0	1 Year
HighVista Strategies LLC	0	0	One Year
Charles Schwab	0	0	1 Year

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. To approve an amendment to our Amended and Restated Employee Stock Purchase Plan;

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 147,375,197AGAINST: 1,468,576

CytomX Therapeutics, Inc.’s own tally for this item (“Proposal 5. The Company's stockholders approved an amendment to the Company's Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement.”): 147,375,197 for, 1,468,576 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 217,702,919 outstanding shares: 68% for, 0.7% against (68% of the company cast a for/against vote).

The 27 asset managers below cast 99.9% of the shares they voted on this item FOR (49,691,564 for, 4 against).

FOR 99.9%

FOR: 49,691,564 (100.0%)AGAINST: 4 (0.0%)

Largest asset managers voting on “To approve an amendment to our Amended and Restated Employee Stock Purchase Plan;” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,436,678	4	For
State Street	4,214,840	0	For
Eversept Partners, LP	2,246,840	0	For
BlackRock	1,426,962	0	For
Dimensional	407,851	0	For
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	111,148	0	For
ALPS ETF Trust	105,410	0	For
WisdomTree	69,157	0	For
ETFis Series Trust I	61,994	0	For
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	37,337	0	For
Gabelli	33,000	0	For
Goldman Sachs	31,185	0	For
FORUM FUNDS II	29,082	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	15,161	0	For
SA FUNDS INVESTMENT TRUST	8,821	0	For
Blackstone Alternative Investment Funds	5,200	0	For
EA Series Trust	3,017	0	For
John Hancock	2,674	0	For
Advisors' Inner Circle Fund III	843	0	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

4. To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Elaine V. Jones, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 131,377,301AGAINST: 17,428,951

CytomX Therapeutics, Inc.’s own tally for this item (“Elect Director: Elaine V. Jones Ph.D.”): 131,377,301 for, 17,428,951 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 217,702,919 outstanding shares: 60% for, 8% against (68% of the company cast a for/against vote).

The 26 asset managers below cast 98% of the shares they voted on this item FOR (46,592,208 for, 852,519 against).

FOR 98%

FOR: 46,592,208 (98.2%)AGAINST: 852,519 (1.8%)

Largest asset managers voting on “To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Elaine V. Jones, Ph.D.” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,420,071	16,610	For
State Street	4,204,556	10,284	For
BlackRock	1,426,962	0	For
Dimensional	0	407,851	Against
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	0	111,148	Against
ALPS ETF Trust	0	105,410	Against
WisdomTree	0	69,157	Against
ETFis Series Trust I	0	61,994	Against
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	0	37,337	Against
Gabelli	33,000	0	For
Goldman Sachs	31,185	0	For
FORUM FUNDS II	29,082	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	0	15,161	Against
SA FUNDS INVESTMENT TRUST	0	8,821	Against
Blackstone Alternative Investment Funds	0	5,200	Against
EA Series Trust	3,017	0	For
John Hancock	0	2,674	Against
Advisors' Inner Circle Fund III	0	843	Against
Direxion Shares ETF Trust	0	29	Against

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

5. To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Matthew P. Young

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 146,742,827AGAINST: 2,062,471

CytomX Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew P. Young”): 146,742,827 for, 2,062,471 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 217,702,919 outstanding shares: 67% for, 1.0% against (68% of the company cast a for/against vote).

The 26 asset managers below cast 99% of the shares they voted on this item FOR (46,967,912 for, 476,815 against).

FOR 99%

FOR: 46,967,912 (99.0%)AGAINST: 476,815 (1.0%)

Largest asset managers voting on “To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Matthew P. Young” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,420,113	16,568	For
State Street	4,209,445	5,395	For
BlackRock	1,426,962	0	For
Dimensional	0	407,851	Against
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	111,148	0	For
ALPS ETF Trust	105,410	0	For
WisdomTree	69,157	0	For
ETFis Series Trust I	61,994	0	For
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	0	37,337	Against
Gabelli	33,000	0	For
Goldman Sachs	31,185	0	For
FORUM FUNDS II	29,082	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	15,161	0	For
SA FUNDS INVESTMENT TRUST	0	8,821	Against
Blackstone Alternative Investment Funds	5,200	0	For
EA Series Trust	3,017	0	For
John Hancock	2,674	0	For
Advisors' Inner Circle Fund III	0	843	Against
Direxion Shares ETF Trust	29	0	For

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

6. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 182,976,052AGAINST: 382,681

CytomX Therapeutics, Inc.’s own tally for this item (“Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”): 182,976,052 for, 382,681 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 217,702,919 outstanding shares: 84% for, 0.2% against (84% of the company cast a for/against vote).

The 26 asset managers below cast 99.9% of the shares they voted on this item FOR (47,444,559 for, 169 against).

FOR 99.9%

FOR: 47,444,559 (100.0%)AGAINST: 169 (0.0%)

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,436,682	0	For
State Street	4,214,671	169	For
BlackRock	1,426,962	0	For
Dimensional	407,851	0	For
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	111,148	0	For
ALPS ETF Trust	105,410	0	For
WisdomTree	69,157	0	For
ETFis Series Trust I	61,994	0	For
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	37,337	0	For
Gabelli	33,000	0	For
Goldman Sachs	31,185	0	For
FORUM FUNDS II	29,082	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	15,161	0	For
SA FUNDS INVESTMENT TRUST	8,821	0	For
Blackstone Alternative Investment Funds	5,200	0	For
EA Series Trust	3,017	0	For
John Hancock	2,674	0	For
Advisors' Inner Circle Fund III	843	0	For
Direxion Shares ETF Trust	29	0	For

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

7. To approve an amendment to our Amended and Restated 2015 Equity Incentive Plan;

COMPENSATION

Combines 2 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 99.8%

The 25 asset managers below cast 99.8% of the shares they voted on this item FOR (47,359,671 for, 55,973 against).

FOR: 47,359,671 (99.9%)AGAINST: 55,973 (0.1%)

Largest asset managers voting on “To approve an amendment to our Amended and Restated 2015 Equity Incentive Plan;” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,420,113	16,566	For
State Street	4,209,276	5,564	For
BlackRock	1,426,962	0	For
Dimensional	407,851	0	For
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	111,148	0	For
ALPS ETF Trust	105,410	0	For
WisdomTree	69,157	0	For
ETFis Series Trust I	61,994	0	For
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	37,337	0	For
Gabelli	0	33,000	Against
Goldman Sachs	31,185	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	15,161	0	For
SA FUNDS INVESTMENT TRUST	8,821	0	For
Blackstone Alternative Investment Funds	5,200	0	For
EA Series Trust	3,017	0	For
John Hancock	2,674	0	For
Advisors' Inner Circle Fund III	0	843	Against
Direxion Shares ETF Trust	29	0	For
First Trust	0	0	--

8. To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares;

CAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 25 asset managers below cast 99.9% of the shares they voted on this item FOR (47,392,796 for, 22,848 against).

FOR: 47,392,796 (100.0%)AGAINST: 22,848 (0.0%)

Largest asset managers voting on “To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of aut” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	30,968,895	0	For
Vanguard	9,420,112	16,568	For
State Street	4,209,403	5,437	For
BlackRock	1,426,962	0	For
Dimensional	407,851	0	For
Tema ETF Trust	231,951	0	For
Charles Schwab	128,796	0	For
ProShares	111,148	0	For
ALPS ETF Trust	105,410	0	For
WisdomTree	69,157	0	For
ETFis Series Trust I	61,994	0	For
Invesco	58,752	0	For
Northern Trust	38,231	0	For
Jackson National	37,337	0	For
Gabelli	33,000	0	For
Goldman Sachs	31,185	0	For
ETF Opportunities Trust	17,710	0	For
Victory Capital	15,161	0	For
SA FUNDS INVESTMENT TRUST	8,821	0	For
Blackstone Alternative Investment Funds	5,200	0	For
EA Series Trust	3,017	0	For
John Hancock	2,674	0	For
Advisors' Inner Circle Fund III	0	843	Against
Direxion Shares ETF Trust	29	0	For
First Trust	0	0	--

9. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

ONE YEAR 98%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (29,082 for, 0 against).

FOR: 29,082 (1.3%)ABSTAIN: 26,265 (1.1%)ONE YEAR: 2,253,600 (97.6%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Eversept Partners, LP	0	0	One Year
FORUM FUNDS II	29,082	0	For
MANGROVE PARTNERS IM, LLC	0	26,265	Abstain
APG Asset Management US Inc.	0	0	One Year

10. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (2,282,682 for, 0 against).

FOR: 2,282,682 (98.9%)ABSTAIN: 26,265 (1.1%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Eversept Partners, LP	2,246,840	0	For
FORUM FUNDS II	29,082	0	For
MANGROVE PARTNERS IM, LLC	0	26,265	Abstain
APG Asset Management US Inc.	6,760	0	For

11. Amend Omnibus Stock Plan

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 147,375,197AGAINST: 1,468,576

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2,275,922 for, 0 against).

FOR 100%

FOR: 2,275,922 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at CytomX Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	2,246,840	0	0	0	For
FORUM FUNDS II	29,082	0	0	0	For

Largest CytomX Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of CytomX Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 217,702,919 shares outstanding at the time of that meeting.

Top CytomX Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	29.07%
2	Kynam Capital Management, LP	8.30%
3	Vanguard	4.96%
4	Point72	3.70%
5	PERCEPTIVE ADVISORS LLC	3.06%
6	BlackRock	2.42%
7	State Street	2.31%
8	Venrock Adviser, LLC	2.29%
9	Siren, L.L.C.	1.59%
10	Wellington	1.22%

Reported CytomX Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CytomX Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.68%	13F
FMR LLC	11.34%	DEF14A
Patrick G. Enright	7.02%	13G
BANK OF AMERICA CORP /DE/	6.95%	13G
Longitude Capital Partners V, LLC	5.30%	DEF14A
Perceptive Advisors LLC	4.64%	13G
Venrock Healthcare Capital Partners III, L.P.	4.59%	13G
Vanguard Group	3.89%	13F
Point72 Asset Management, L.P.	3.59%	13G
Citadel Advisors	2.71%	13F

Percentages above are of 217,702,919 shares outstanding, as reported by CytomX Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CytomX Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CytomX Therapeutics, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 115 asset managers reported how they voted in their SEC Form N-PX filings, covering 939 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a nonbinding advisory basis, the compensation of the Company's named executive… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CytomX Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-22.

CytomX Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).